“Emma.”
“I’m going to Harrington BioSystems.”
Naomi let out a slow breath. “Then I am meeting you there.”
Harrington BioSystems was the family’s crown jewel, a medical technology company with a shining public reputation and a decaying financial foundation. Six months before the wedding, I had uncovered that Ryan’s father had hidden failed trials, bribed procurement officials, and used charitable foundations to move dirty money through foreign accounts.
I had not set out to find any of it at first. I had only wanted to understand why Ryan was rushing marriage, why his mother wanted me to abandon my work, why his father asked too many questions about my “small consulting clients.”
The further I dug, the more obvious the truth became.
They had not wanted a daughter-in-law.
They had wanted access.
My late father had left me a minority share in a pharmaceutical logistics company he had quietly invested in years earlier. That company controlled distribution rights Harrington urgently needed for a federal contract worth hundreds of millions.
